Global Postpartum Depression Market to reach USD 55.24 billion by 2031 grow at a CAGR of 30.25%, Psychotherapy holds 45.3% of market revenue.

The Global Postpartum Depression Market size in 2023 is USD 8.68 billion. The market share is projected to grow at a CAGR of 30.25% and reach USD 55.24 billion by 2031.

Download your exclusive sample report today: (corporate email gets priority access):https://www.datamintelligence.com/download-sample/postpartum-depression-market?pratik

United States: Key Industry Developments
✅ August 2025: Sage Therapeutics and Marinus Pharmaceuticals advanced therapies like SAGE-217 and ganaxolone for postpartum depression treatment, strengthening their market positions amid rising mental health investments.​

✅ Ongoing 2025: Anti-depressant drugs, including SSRIs such as sertraline, fluoxetine, and escitalopram, dominated the postpartum depression management market with 38.2% revenue share, driven by proven efficacy for maternal mood improvement.

Benefits of Purchase the Report?
→ To visualize the global postpartum depression market segmentation based on type, treatment, end-user and region as well as understand key commercial assets and players.
→ Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of postpartum depression market-level with all segments.
→ PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
→ Product mapping available as excel consisting of key products of all the major players.
→ The global postpartum depression market report would provide approximately 61 tables, 58 figures, and 186 Pages.

"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=postpartum-depression-market?pratik ((Purchase 2 or more Repots and get 50% Discount)

Market Segmenatation-
Segmentation by Treatment Type (sizes / notes)
→ Psychotherapy: USD 980.4 million (45.3% of market, 2025 est.) - Psychotherapy (CBT, IPT and other talk therapies) is reported as the largest treatment segment and was estimated at 45.3% of the market; applied to the 2025 total gives USD 980.4M.

→ Antidepressant medications (pharmacotherapy): Reported values vary by report / scope. One market source reports antidepressant medications valued at USD 900 million (2024) within the larger postpartum/maternal-mental health space (this aligns with pharmacotherapy being a major revenue contributor). Use-case: pharmacotherapy remains core for moderate-to-severe PPD.

→ Hormonal therapy / Neuroactive-steroid antidepressants: (Growing niche) - Several analyses highlight neuroactive-steroid antidepressants (e.g., brexanolone-class drugs) as a high-growth subsegment; reported CAGR for this class is strong, but exact 2025 revenue split is not uniformly published. (Source notes neuroactive-steroid class is projected to grow rapidly).

→ Lifestyle modifications & Other non-drug interventions: (Smaller share vs psychotherapy & meds) - Included in "other" treatment buckets; no single authoritative 2025 value published across the primary reports I searched (these are typically folded into psychotherapy/"other" in major reports).

Segmentation by Route of Administration (sizes)
→ Oral formulations: USD 1,564.7 million (72.3% of market, 2025 est.) - Reports indicate oral route dominates therapeutics for PPD; applying the reported 72.3% share to the 2025 market total yields USD 1,564.7M.

→ Parenteral / Injectables (e.g., IV or infusion neuroactive steroids): (Material but much smaller than oral) - Parenteral products (e.g., brexanolone IV) are high-value but limited by administration setting; most reports treat this as a minority share vs oral. Exact 2025 $ not uniformly published.

Key Developments
✅ June 2025: Supernus Pharmaceuticals filed a tender offer statement with the U.S. Securities and Exchange Commission, a notable corporate development in the broader central nervous system (CNS) disease space relevant to the market.

✅ April 2025: The Postpartum Depression Market Report 2025 highlighted that regulatory flexibility in approving alternative formulations and digital therapeutic platforms is helping maintain continuity of care despite potential tariff-related supply chain pressures.

✅ Pranaiya and Arthur Magoffin Foundation (PAM Foundation) is proud to announce a collaboration with the University of Oxford focused on postpartum depression (PPD) and other perinatal mental health illnesses.

Regional insights:-

• North America -39% share (largest regional market)
North America (led by the U.S.) is the largest region, capturing roughly 37-39% of the market in the most recent published analyses. Growth is driven by high screening rates, faster regulatory approvals for new neurosteroid and novel PPD therapies, broad payer coverage and strong clinical-trial activity. Sources:

• Asia-Pacific - 34% share (fastest expanding by CAGR)
Asia-Pacific is the fastest-growing regional market and is estimated to hold about 34% of global PPD market value (large, rising patient base in China, India and Japan; expanding mental-health infrastructure; increasing adoption of pharmacological and non-pharmacological treatments).

• Europe - 22% share (mature, reimbursement-driven uptake)
Europe represents roughly 22% of market value. Uptake is steady and shaped by national public health programs, health-technology assessment (HTA) scrutiny, and growing integration of maternal-mental-health services in perinatal care pathways (Western Europe leads; Central/Eastern Europe trails).

Competitive Landscape:-

→ Biogen Pharmaceuticals, Sage Therapeutics, Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc, Mallinckrodt Pharmaceuticals, Dr. Reddy's Laboratories, Sandoz, Amneal Pharmaceuticals Pvt. Ltd., and Servier Laboratories Ltd. among others.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/postpartum-depression-market?pratik

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.

This release was published on openPR.